Results 181 to 190 of about 35,674 (297)

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Use of select medications prior to duloxetine initiation among commercially-insured patients

, 2012
Mark Bernauer,1 Ning Wu,2 Shih-Yin Chen,2 Xiaomei Peng,1 Luke Boulanger,2 Yang Zhao11Eli Lilly and Company, Indianapolis, IN, 2United BioSource Corporation, Lexington, MA, USABackground: The purpose of this study was to assess select medication ...
Peng X, Chen SY, Bernauer M, Wu N, Zhao Y, Boulanger L   +5 more
core  

Opioid use disorder deaths and the effects of medication therapy [PDF]

The American Journal of Drug and Alcohol Abuse, 2019
Mannelli, Paolo, Wu, Li-Tzy
openaire   +2 more sources

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

A mixed methods analysis of clinics' perspectives on community factors influencing access to medications for opioid use disorder. [PDF]

Addict Sci Clin Pract
Jaros S, Magid MA, Cheng H, Gassman M, Garneau HC, Ford Ii JH, McGovern M.   +6 more
europepmc   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

State Proposed Strategies to Expand Access to Medications for Opioid Use Disorder. [PDF]

Health Serv Res
Baron A, Hall JD, Byers J, Lindner S, Cohen DJ.   +4 more
europepmc   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Impact of study design decisions on identification of treatment initiators of medications for opioid use disorder. [PDF]

Addiction
Roy PJ, Colvin R, Nickel KB, Ross RK, Durkin MJ, Suda KJ, Atkinson A, Butler AM.   +7 more
europepmc   +1 more source

Theorizing causality: A qualitative study of xylazine‐related wound diversity and perceived etiology among people who inject drugs

Addiction, EarlyView.
Abstract Background and aims Incidence and severity of opioid‐associated skin and soft‐tissue infections, often requiring intensive and costly medical care, have increased substantially since the emergence of xylazine in the US drug supply. Although progress has been made in clinical and harm reduction recommendations for treating xylazine‐related ...
Danielle German, Kelci Villarroel, Meredith Denney, Adrian Guta, Julie Evans, Jason Bienert, Alex Fidler, Kim Ashburn, Zach Kosinski, Becky L. Genberg   +9 more
wiley   +1 more source